Darolutamide
See how this compound is being investigated across Bayer’s oncology pipeline
Explore the tumor types, areas of research, and clinical trials associated with this investigational compound.
Compound Overview
Darolutamide* is a structurally distinct androgen receptor (AR) inhibitor with high-affinity binding to ARs, thereby preventing testosterone from binding and inhibiting nuclear translocation of the AR complex.1-3
*In collaboration with Orion Pharma.
Clinical Trials
Tumor Type(s) | Phase | Status | Description | NCT Number |
|---|---|---|---|---|
Prostate Cancer | III | Active, Not Enrolling | Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate (DASL-HiCaP) | |
Prostate Cancer | III | Active, Not Enrolling | An Open-label, Single Arm, Roll-over Study to Provide Continued Treatment With Darolutamide in Participants Who Were Enrolled in Previous Bayer Sponsored Studies | |
Prostate Cancer | III | Active, Not Enrolling | A Randomized, Double-blind, Placebo-controlled Phase 3 Study of Darolutamide Plus Androgen Deprivation Therapy (ADT) Compared With Placebo Plus ADT in Patients With High-risk Biochemical Recurrence (BCR) of Prostate Cancer | |
Prostate Cancer | Non-interventional Study | Active, Not Enrolling | Darolutamide Observational Study in Non-metastatic Castration-resistant Prostate Cancer Patients | |
Prostate Cancer | Non-interventional Study | Now Enrolling | A Multicenter, Real-world Study Evaluating the Effectiveness of Darolutamide Plus ADT in Patients Progressing to nmCRPC After Bicalutamide Plus ADT Treatment During nmHSPC Stage | |
Prostate Cancer | Non-interventional Study | Now Enrolling | Post-marketing Surveillance Study for Approved Darolutamide Use in Korean Patients | |
Prostate Cancer | Non-interventional Study | Now Enrolling | An Observational Study of Darolutamide in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Patients With Low-volume Metastatic Hormone-sensitive Prostate Cancer | |
Prostate Cancer | Non-interventional Study | Active, Not Enrolling | ROAD - Real-World Outcomes of Darolutamide, ADT, With or Without Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer |
Bayer’s Oncology Pipeline Brochure
Explore a comprehensive overview of Bayer's oncology pipeline, including investigational compounds, clinical trials, and areas of research.
The ongoing clinical trials listed on this website represent a comprehensive overview of Bayer's clinical pipeline in Oncology, including Bayer-sponsored research and collaborative research with academic centers, cooperative groups, and other global institutions.